Editions:  Austria · Denmark · France · Germany · Italy · Norway · Spain · Sweden · Switzerland
Advertisement

Roche drug linked to fatal skin reactions in Canada

Share this article

Roche drug linked to fatal skin reactions in Canada
Photo: Roche
21:45 CET+01:00
A drug used to treat advanced breast and colorectal cancers has been linked to sometimes fatal skin reactions in patients, its Swiss manufacturer Roche and Canadian health officials said on Wednesday.

Xeloda, which treats advanced cancer after complete surgical removal, can cause "severe skin reactions," Health Canada said in a statement.
   
It said patients had reported severe skin reactions, such as the life-threatening skin condition known as Stevens-Johnson Syndrome or toxic epidermal necrolysis.
   
The signs and symptoms of this hypersensitivity include flu-like symptoms, fever, itchy skin, mouth sores, as well as painful, red or purplish skin rash that spreads and blisters, causing the top of the skin to shed, along with eye burning, itching and discharge.

Health Canada urged patients using Xeloda to contact their physician "immediately" after experiencing any of those signs or symptoms, so that they may report these adverse reactions to Roche or Health Canada.
   
Following requests from Canadian health authorities, Hoffmann-La Roche said it will be working with Health Canada to update the drug's prescribing information document.
   
It has sent a letter to healthcare professionals warning of the "risk of severe cutaneous reactions associated with the use of Xeloda," though it said that those cases were "very rare."

Get notified about breaking news on The Local

Share this article

Advertisement

From our sponsors

The Swedish university tackling the challenges of tomorrow

Ranked among the world’s best young universities in the QS Top 50 Under 50, Linköping University (LiU) uses innovative learning techniques that prepare its students to tackle the challenges of tomorrow.

Advertisement
Advertisement
Jobs
Click here to start your job search
Advertisement
Advertisement

Popular articles

Advertisement
Advertisement